Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma

Investigational New Drugs

Volumn 28, Issue 5, 2010, Pages 670-676

  Wu, Jennifer ^a,h   Henderson, Charles ^b   Feun, Lynn ^c   Van Veldhuizen, Peter ^d   Gold, Philip ^e   Zheng, Hui ^g   Ryan, Theresa ^a   Blaszkowsky, Lawrence S ^g   Chen, Haobin ^a   Costa, Max ^a   Rosenzweig, Barry ^a   Nierodzik, Marylynn ^a   Hochster, Howard ^a   Muggia, Franco ^a   Abbadessa, Giovanni ^f   Lewis, Jonathan ^f   Zhu, Andrew X ^g  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PIEDMONT HOSPITAL   (United States)

^c UNIVERSITY OF MIAMI HOSPITAL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e SWEDISH MEDICAL CENTER   (United States)

^f Ziopharm Oncology Inc   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h BELLEVUE HOSPITAL CENTER   (United States)

Author keywords

Clinical trials; Darinaparsin; Hepatocellular carcinoma; Phase II study

Indexed keywords

DARINAPARSIN; ORGANOARSENIC DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUTATHIONE;

ABDOMINAL PAIN; ADULT; AGITATION; ANOREXIA; ARTICLE; ASCITES; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; MALE; MORTALITY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; RASH; SIDE EFFECT; TASTE DISORDER; VOMITING; WHEEZING; AGED; ANALOGS AND DERIVATIVES; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; DISEASE FREE SURVIVAL; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ARSENICALS; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; GLUTATHIONE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 77956060553     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-009-9286-9     Document Type: Article

References (32)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer statistics CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010 18287387
2. HB El-Serag JA Davila NJ Petersen KA McGlynn 2003 The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update Ann Intern Med 139 817 823 14623619
3. HK Weir MJ Thun BF Hankey LA Ries HL Howe PA Wingo A Jemal E Ward RN Anderson BK Edwards 2003 J Natl Cancer Inst 95 1276 1299 12953083
4. SF Altekruse KA McGlynn ME Reichman 2009 Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005 J Clin Onc 27 1485 1491 10.1200/JCO.2008.20.7753
5. JM Llovet S Ricci V Mazzaferro P Hilgard E Gane JF Blanc AD de Oliverira A Santoro JL Raoul A Forner M Schwartz C Porta S Zeuzem L Bolondi TF Greten PR Galle JF Seitz I Borbath D Haussinger T Giannaris M Shan M Moscovici D Voliotis J Bruix 2008 Sorafenib in advanced hepatocellular carcinoma NEJM 359 378 390 10.1056/NEJMoa0708857 1:CAS:528:DC%2BD1cXovFWjsL8%3D 18650514
6. AL Cheng YK Kang Z Chen CJ Tsao S Qin JS Kim R Lou J Feng S Ye TS Yang J Xu Y Sun H Liang J Liu J Wang WY Tak H Pan K Burock J Zou D Voliotis Z Guan 2008 Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet 10 25 34
7. HY Xu YL Yang SM Liu L Bi SX Chen 2004 Effect of arsenic trioxide on human hepatocarcinoma in nude mice World J Gastroenterol 10 3677 3679 1:CAS:528:DC%2BD2MXjs12gsg%3D%3D 15534931
8. M Kito K Matsumoto N Wada K Sera S Futatsugawa T Naoe Y Nozawa Y Akao 2003 Antitumor effect of arsenic trioxide in murine xenograft model Cancer Sci 94 1010 1014 10.1111/j.1349-7006.2003.tb01393.x 1:CAS:528:DC%2BD2cXhsF2mtA%3D%3D 14611680
9. B Tan BF Huang Q Wei H Zhang RZ Ni 2005 Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetamidofluorene in rats World J Gastroenterol 11 5938 5943 1:CAS:528:DC%2BD28XhtlKns7Y%3D 16273603
10. T Zhang SS Wang L Hong XL Wang QH Qi 2003 Arsenic trioxide induces apoptosis of rat hepatocellular carcinoma cells in vivo J Exp Clin Cancer Res 22 61 68 12725324
11. J Qian S Qin Z He 2001 Arsenic trioxide in the treatment of advanced primary liver and gallbladder cancer Zhonghua Zhongliu Zazhi 23 487 489 1:STN:280:DC%2BD387isFaiug%3D%3D 11859717
12. J Qian SK Qin ZM He L Wang YX Chen ZJ Shao XF Liu 2002 Arsenic trioxide for the treatment of medium and advanced primary liver cancer Zhonghua Ganzhangbing Zazhi 10 63
13. CC Lin C Hsu CH Hsu W Hsu AL Cheng CH Yang 2007 Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial Invest New Drugs 25 73 84 10.1007/s10637-007-9034-y 1:CAS:528:DC%2BD1cXlslansQ%3D%3D
14. Goyer RA (1996) Toxic effects of metals. In: Klassen CD (ed) Casarett and Doull's toxicology: the basic science of poisons, 5th edn. McGraw-Hill, New York, pp 691-698
15. T Jean JC Barbey SL Pezzullo 2003 Effect of arsenic trioxide on QT interval in patients with advanced malignancies J Clin Onc 21 3609 3615 10.1200/JCO.2003.10.009
16. A Quitas-Cardama S Verstovsek E Freireich H Kantarjian YW Chen R Zingaro 2008 Chemical and clinical development of darinaparsin, a novel organic arsenic derivative Anticancer Agnets Med Chem 8 904 908
17. T Manshouri SV Kala F Ashoori R Zingaro EJ Frieireich M Andreeff HM Kantarjian S Verstovsek 2005 Comparison of uptake and intracellular induced structural changes of arsenic trioxide, an inorganic compound, and organic arsenic derivative S-dimethylarsino-glutathione in NB4 APL cells Blood, Proc Ame Soc Hem 106 A# 4446
18. 3-resistant and MRP1/ABCC1-overexpressing cell lines Leukemia 22 1853 1863 10.1038/leu.2008.194 1:CAS:528:DC%2BD1cXht1Cms77N 18633430
19. DeVita VT, DeVita VT Jr, Lawrence TS, Rosenberg SA (2005) Cancer principles and practice of oncology, 7th edn. Lippincott Williams And Wilkins, Philadelphia Chapter 24.2, 619
20. P Therasse SG Arbuck EA Eisenhauer J Wanders RS Kaplan L Rubinstein J Verweij M Van Glabbeke AT van Oosterom MC Christian SG Gwyther 2000 New guidelines to evaluate the response to treatment in solid tumors J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
21. H Chen S Li J Liu BA Diwan JC Barrett MP Waalkes 2004 Chronic inorganic arsenic exposure induces hepatic global and individual gene hypomethylation: implications for arsenic hepatocarcinogenesis Carcinogenesis 25 1779 1786 10.1093/carcin/bgh161 1:CAS:528:DC%2BD2cXntFaitbk%3D 15073043
22. Y Xie KJ Trouba J Liu MP Waalkes DR Germolec 2004 Biokinetics and subchronic toxic effects of oral arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid in v-Ha-ras transgenic (Tg.AC) mice Environ Health Perspect 112 1255 1263 1:CAS:528:DC%2BD2cXotVKjtL4%3D 15345372
23. JF Reichard M Schnekenburger A Puga 2007 Long term low-dose arsenic exposure induces loss of DNA methylation Biochem Biophys Res Commun 352 188 192 10.1016/j.bbrc.2006.11.001 1:CAS:528:DC%2BD28Xht1Oht7rE 17107663
24. Y Lee L Broday M Costa 1998 Effects of nickel on DNA methyltransferase activity and genomic DNA methylation levels Mutation Res 415 213 218 1:CAS:528:DyaK1cXks1Ont74%3D 9714811
25. P Arbuthnot A Capovilla M Kew 2000 Putative role of hepatitis B virus X protein in hepatocarcinogenesis: effects on apoptosis, DNA repair, mitogen-activated protein kinase and JAK/STAT pathways J Gastroenterol Hepatol 15 357 368 10.1046/j.1440-1746.2000.02069.x 1:CAS:528:DC%2BD3cXktVOmtbo%3D 10824878
26. JH Lei XE He X Yang M Zhang J Lian HY Luo WL Wang 2007 Effects of HBV X gene and arsenic trioxide on the expression of p53 in cultured HepG2 cells Chin Med J (Engl) 120 2181 2184 1:CAS:528:DC%2BD1cXht12ltL4%3D
27. I Lossos MS Craig RV Tallman PR Boccia C Conkling PB Becerra B Komarnitsky J Hamilton Lewis WH Miller 2009 Novel organic arsenic molecule darinaparsin: development of IV and oral forms J Clin Onc, Proc Am Soc Clin Onc 27 15S A#8501
28. JR Berenson S Jaganath D Reece R Boccia R Soebel A Belch B Schwartz RP Gale M Hussein 2007 ZIO-101 (S-dimethylarsino-glutathione): phase I/II trials in advanced/progressive multiple myeloma J Clin Onc, Proc Am Soc Clin Onc 25 18S A#8109
29. JR Berenson RVV Boccia A Hussein A Belch L Boise B Schwartz RP Gale SM Kornblau 2006 Phase-1 study of ZIO-101: a new organic arsenic active in acute myelogenous leukemia (AML) and multiple myeloma (MM) Blood, Proc Am Soc Hem 108 A#1966
30. C Campas R Castaner 2009 Darinaparsin Drugs Future 34 97 10.1358/dof.2009.034.02.1337397 1:CAS:528:DC%2BD1MXmtVWjt7c%3D
31. B Liu S Pan X Dong H Qiao H Jiang GW Krissansen X Sun 2006 Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice Cancer Sci 97 675 681 10.1111/j.1349-7006.2006.00230.x 1:CAS:528:DC%2BD28XmsVOntLc%3D 16827809
32. M Fei M Lu Y Wang Y Zhao S He S Gao Q Ke Y Liu P Li X Cui A Shen C Cheng 2009 Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization Med Oncol 26 178 185 10.1007/s12032-008-9105-8 1:CAS:528:DC%2BD1MXmtVKit78%3D 18937079